share_log

Here's What's Concerning About Micro-Tech (Nanjing)Ltd's (SHSE:688029) Returns On Capital

Here's What's Concerning About Micro-Tech (Nanjing)Ltd's (SHSE:688029) Returns On Capital

以下是南微醫學(南京證券股份有限公司:688029)資本回報方面值得關注的問題
Simply Wall St ·  06/19 22:51

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expanding base of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. Having said that, from a first glance at Micro-Tech (Nanjing)Ltd (SHSE:688029) we aren't jumping out of our chairs at how returns are trending, but let's have a deeper look.

如果我們想要識別長期內股票的增值趨勢,應該尋找什麼趨勢?通常,我們希望注意到資本利用率增長的趨勢。基本上,這意味着一家公司擁有有利可圖的計劃,可以繼續投資,這是一個複合機器的特徵。然而,當我們看Methode Electronics (NYSE:MEI)時,似乎沒有完全滿足這些條件。資產回報率:它是什麼?對於那些不知道ROCE是什麼的人,ROCE是一個公司每年稅前利潤(回報)與企業用於投資的資本關係的度量。在Elevance Health的計算公式如下:資產回報率 = 利息和所得稅前收益(EBIT)÷(總資產-流動負債)基本上,資金使用效率是指一家公司有盈利的初創項目可以持續投資,這是一個複利機器的特點。然而,就南微醫學(Nanjing)有限公司(SHSE:688029)的收益走勢而言,我們並不對此感到激動,但我們可以深入研究一下。

Return On Capital Employed (ROCE): What Is It?

資本僱用回報率(ROCE)是什麼?

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. Analysts use this formula to calculate it for Micro-Tech (Nanjing)Ltd:

對於不了解情況的人來說,ROCE是公司年度稅前利潤(收益)與業務中的資本的比率。分析師用這個公式計算南微醫學(Nanjing)有限公司的ROCE:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

資產僱用回報率(ROCE)是指企業利潤,即企業稅前利潤除以企業投入的總資本(負債加股權)。如果ROCE高於企業財務成本的承受能力,那麼企業就會創造出更多的價值。

0.13 = CN¥499m ÷ (CN¥4.4b - CN¥518m) (Based on the trailing twelve months to March 2024).

0.13 = CN¥49900萬 ÷ (CN¥44億 - CN¥518m)在Elevance Health上,我們已經注意到的趨勢是相當令人放心的。數據顯示,過去五年資產回報率大幅提高至15%。投資所用資產的規模也增加了30%。這表明有很多機會進行內部資本投資,並以更高的速度不斷增長,這種組合在多倍增長方面很常見。.

So, Micro-Tech (Nanjing)Ltd has an ROCE of 13%. On its own, that's a standard return, however it's much better than the 6.3% generated by the Medical Equipment industry.

所以,南微醫學(Nanjing)有限公司的ROCE爲13%。單獨來看,這是一個標準的回報,但比醫療設備行業的6.3%要好得多。

roce
SHSE:688029 Return on Capital Employed June 20th 2024
SHSE:688029 資本運用回報率2024年6月20日

In the above chart we have measured Micro-Tech (Nanjing)Ltd's prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Micro-Tech (Nanjing)Ltd .

在上面的圖表中,我們已經測量了南微醫學(Nanjing)有限公司以往的ROCE和以往的業績,但未來則更加重要。如果你想要查看分析師的預測,請查看我們的南微醫學(Nanjing)有限公司免費分析師報告。

The Trend Of ROCE

當尋找下一個倍增器時,如果您不確定從哪裏開始,請關注幾個關鍵趨勢。首先,我們希望看到一個經過驗證的資本使用率。如果您看到這一點,通常意味着這是一家擁有出色業務模式和大量盈利再投資機會的公司。然而,調查蒙托克可再生能源公司(NASDAQ:MNTK)後,我們認爲它的現行趨勢不符合倍增器的模式。

On the surface, the trend of ROCE at Micro-Tech (Nanjing)Ltd doesn't inspire confidence. Over the last five years, returns on capital have decreased to 13% from 31% five years ago. Although, given both revenue and the amount of assets employed in the business have increased, it could suggest the company is investing in growth, and the extra capital has led to a short-term reduction in ROCE. And if the increased capital generates additional returns, the business, and thus shareholders, will benefit in the long run.

表面上看,南微醫學(Nanjing)有限公司ROCE的趨勢並沒有提高人們的信心。在過去的五年中,資本回報率從五年前的31%下降到了13%。儘管營業收入和資產的數量都在增加,但這可能表明公司正在投資於增長,而額外的資本導致了ROCE的短期下降。如果增加的資本產生了額外的收益,業務和股東將從中獲益,進而從長遠來看受益。

On a related note, Micro-Tech (Nanjing)Ltd has decreased its current liabilities to 12% of total assets. So we could link some of this to the decrease in ROCE. Effectively this means their suppliers or short-term creditors are funding less of the business, which reduces some elements of risk. Since the business is basically funding more of its operations with it's own money, you could argue this has made the business less efficient at generating ROCE.

相關的是,南微醫學(Nanjing)有限公司已經將其流動負債降低到總資產的12%。因此,我們可以將其中一部分歸因於ROCE的下降。實際上,這意味着他們的供應商或短期債權人資助的業務更少,這減少了某些風險。由於業務基本上用自己的資金更多地資助其自身的運作,因此可以認爲這使得業務在產生ROCE方面不那麼高效。

Our Take On Micro-Tech (Nanjing)Ltd's ROCE

我們對南微醫學(Nanjing)有限公司的ROCE觀點

In summary, despite lower returns in the short term, we're encouraged to see that Micro-Tech (Nanjing)Ltd is reinvesting for growth and has higher sales as a result. And there could be an opportunity here if other metrics look good too, because the stock has declined 69% in the last three years. As a result, we'd recommend researching this stock further to uncover what other fundamentals of the business can show us.

總的來說,儘管短期回報較低,但我們很高興看到南微醫學(Nanjing)有限公司正在爲增長而重新投資,並因此實現了更高的銷售額。如果其他指標也好的話,這裏可能會有機會,因爲該股票在過去三年中下降了69%。因此,我們建議進一步研究這支股票,以揭示業務的基本面還能夠顯示什麼。

On a separate note, we've found 1 warning sign for Micro-Tech (Nanjing)Ltd you'll probably want to know about.

另外注意到,我們已經發現南微醫學(Nanjing)有限公司有1個預警信號,你可能想了解一下。

While Micro-Tech (Nanjing)Ltd may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here.

雖然南微醫學(Nanjing)有限公司當前的回報並不是最高的,但是我們已經編制了一份目前每年股本回報率高於25%的公司列表。請在這裏查看此免費列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論